<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <title>HELIXMITH</title>
    <link type="text/css" rel="stylesheet" href="css/reset.css" />
    <link type="text/css" rel="stylesheet" href="css/style.css" />
    <link type="text/css" rel="stylesheet" href="css/animate.css" />
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
</head>

<body>
    <!--wrapper-->
    <div class="wrapper">
        <!--headNavigation-->
        <div class="headNavigation headImage3 wow fadeIn">
            <!--inside-->
            <div class="inside">
                <!--menus-->
                <div class="menus">
                    <!--logo-->
                    <div class="left">
                        <a href="index.html">
                            <img src="img/logo.svg">
                        </a>
                    </div>
                    <!--//logo-->
                    <div class="right">
                        <ul class="pc">
                            <li>
                                <a href="about_1.html">
                                    About Helixmith
                                </a>
                                <div class="dropdown-content">
                                    <div class="box">
                                        <a href="about_1.html">
                                            <p>
                                                Our Company
                                            </p>
                                        </a>
                                        <a href="about_2.html">
                                            <p>
                                                Our People
                                            </p>
                                        </a>
                                        <a href="about_4.html">
                                            <p>
                                                Our Advisors
                                            </p>
                                        </a>
                                        <a href="about_3.html">
                                            <p>
                                                Locations
                                            </p>
                                        </a>
                                    </div>
                                </div>
                            </li>
                            <li>
                                <a href="vm202.html">
                                    Flagship Product Engensis
                                </a>
                                <div class="dropdown-content">
                                    <div class="box">
                                        <a href="vm202.html#first">
                                            <p>
                                                Overview
                                            </p>
                                        </a>
                                        <a href="vm202_dpn.html#first">
                                            <p>
                                                Engensis in DPN
                                            </p>
                                        </a>
                                        <a href="vm202_dpn.html#second">
                                            <p>
                                                Engensis in DFU
                                            </p>
                                        </a>
                                        <a href="vm202_dpn.html#third">
                                            <p>
                                                Engensis in ALS
                                            </p>
                                        </a>
                                        <a href="vm202_dpn.html#fourth">
                                            <p>
                                                Engensis in CAD
                                            </p>
                                        </a>
                                        <a href="vm202_pub.html">
                                            <p>
                                                Publications
                                            </p>
                                        </a>
                                    </div>
                                </div>
                            </li>
                            <li>
                                <a href="platform.html">
                                    Early Phase Programs
                                </a>
                                <div class="dropdown-content">
                                    <div class="box">
                                        <a href="platform.html#first">
                                            <p>
                                                Neuromyon
                                            </p>
                                        </a>
                                        <!-- <a href="platform.html#second">
                                            <p>
                                                Chimericsmith
                                            </p>
                                        </a> -->
                                        <a href="platform.html#third">
                                            <p>
                                                Oncosmith
                                            </p>
                                        </a>
                                    </div>
                                </div>
                            </li>
                            <!-- <li>
                                <a href="botanicals.html">
                                    CERESMITH
                                </a>
                            </li> -->
                            <li>
                                <a href="/bbs/board.php?bo_table=notice&page=1">
                                    News
                                </a>
                                <div class="dropdown-content">
                                    <div class="box">
                                        <a href="/bbs/board.php?bo_table=notice&page=1">
                                            <p>
                                                News/Investors
                                            </p>
                                        </a>
                                    </div>
                                </div>
                            </li>
                            <li>
                                <a href="careers.html">
                                    Careers
                                </a>
                            </li>
                        </ul>
                        <ul class="mobile displayFlex">
                            <li>
                                <img src="img/mobile_menu_ico.svg" id="showPanel" />
                            </li>
                        </ul>
                    </div>
                </div>
                <!--//menus-->
                <!--content-->
                <div class="content subContent">
                    <h1 class="headText">
                        Engensis®
                    </h1>
                    <h2>
                        (VM202, donaperminogene seltoplasmid)
                    </h2>
                </div>
                <!--//content-->
            </div>
            <!--//inside-->
        </div>
        <!--//headNavigation-->
        <!--1-->
        <div class="vm202Section marginTop50">
            <div class="first">
                <!--text-->
                <div class="text wow fadeIn" id="first">
                    <!--head-->
                    <div class="head">
                        <h1>
                            <span class="textAlignLeft pointColorText">1.</span> Engensis in DPN
                        </h1>
                    </div>
                    <!--//head-->
                    <p>
                        Diabetic peripheral neuropathy (DPN) is one of the most commonly encountered debilitating
                        complication of diabetes, typically presenting with burning, tingling, throbbing, and stabbing
                        pain.
                    </p>
                    <p>
                        About 30 million US adults have diabetes. About 28.5% of diabetics suffer from DPN, and
                        40-50% of those patients suffer from painful DPN. Currently approved medications for PDPN are
                        palliative, only managing the pain, with possible serious side effects and can be highly
                        addictive.
                    </p>
                    <!-- <p>
                        There are 4 naturally occurring HGF isoforms, and two of them, HGF 728 and HGF 723 are the
                        main forms that activates c-Met receptor. At Helixmith, we developed a special cDNA-
                        genome hybrid gene which guarantees the simultaneous expression of HGF 728 and HGF 723
                        to maximize the biological activities of HGF.
                    </p> -->
                    <p>
                        With Engensis, we are trying a new approach. We believe that Engensis reverses the underlying
                        cause of neuropathy through an angio-neurorestorative effect. Because it has this possible
                        mechanism of action, the US FDA granted <b>RMAT (Regenerative Medicine Advanced Therapy)</b>
                        designation to Engensis and we decided to look for this effect in the ongoing Phase III trial in
                        the US.
                    </p>
                    <!--<p>
                    <span class="fontBold">Clinical study information:</span><br>
                    <a href="https://clinicaltrials.gov/ct2/show/NCT02427464?term=viroMed" target="_blank">
                        https://clinicaltrials.gov/ct2/show/NCT02427464?term=viroMed
                    </a>
                </p>-->
                </div>
                <!--//text-->
                <!--safety-->
                <div class="vm202Table wow fadeIn textAlignLeft">
                    <h2>
                        <span class="textAlignLeft">Safety</span>
                    </h2>
                </div>
                <!--//safety-->
                <!--text-->
                <div class="text wow fadeIn">
                    <p>
                        To date, Engensis appears to be relatively safe. In the Phase I and Phase II trials conducted
                        so far, no serious adverse events were found directly attributed to Engensis. And, because the
                        encoded gene is indigenous, immune response concerns that may arise with other gene therapies
                        are less likely to be an issue with Engensis.
                    </p>
                </div>
                <!--//text-->
                <!--eff-->
                <div class="vm202Table wow fadeIn textAlignLeft">
                    <h2>
                        <span class="textAlignLeft">Efficacy</span>
                    </h2>
                </div>
                <!--//eff-->
                <!--text-->
                <div class="text wow fadeIn">
                    <p>
                        Pain scores obtained during clinical trials appear to show long-lasting effects of Engensis
                        on pain severity. Patients who were not on pregabalin or gabapentin appeared to show higher
                        improvement rates, suggesting that Engensis may have better utility as a sole treatment.
                    </p>
                </div>
                <!--//text-->
                <!--divider-->
                <div class="divider"></div>
                <!--//divider-->
                <!--text-->
                <div class="text wow fadeIn" id="second">
                    <!--head-->
                    <div class="head">
                        <h1>
                            <span class="textAlignLeft pointColorText">2.</span> Engensis in DFU
                        </h1>
                    </div>
                    <!--//head-->
                    <p>
                        Diabetic foot ulcers (DFU) can be chronic, non-healing foot ulcers, a major complication of
                        both diabetes and peripheral arterial disease (PAD) that is caused by impediment of the
                        wound-healing process.
                    </p>
                    <p>
                        Over 6.5 million people in the US alone have chronic, non-healing foot ulcers; many of them
                        also have peripheral neuropathy, which results in numbness or pain in the legs and arms. The
                        market size for DFU had grown up to USD 3.6 billion in 2017. Current treatments are limited to
                        wound care dressings or pain management, and 25% of wounds progress to the extent that
                        amputation is required.
                    </p>
                    <p>
                        Engensis is currently under development as a possible fundamental treatment for chronic DFU
                        with the hope that it that can heal the ulcer by supplying sufficient blood through new blood
                        vessel formation around occluded or narrowed blood vessels towards the lower extremities.
                    </p>
                </div>
                <!--//text-->
                <!--safety-->
                <div class="vm202Table wow fadeIn textAlignLeft">
                    <h2>
                        <span class="textAlignLeft">Safety</span>
                    </h2>
                </div>
                <!--//safety-->
                <!--text-->
                <div class="text wow fadeIn">
                    <p>
                        To date, Engensis appears to be relatively safe. In the Phase I and Phase II trials conducted
                        so far, no serious adverse events were found directly attributed to Engensis. And, because the
                        encoded gene is indigenous, immune response concerns that may arise with other gene therapies
                        are less likely to be an issue with Engensis. In addition, the drug is injected locally with no
                        evidence of systemic exposure thus far, which should contribute to a good safety profile.
                    </p>
                </div>
                <!--//text-->
                <!--eff-->
                <div class="vm202Table wow fadeIn textAlignLeft">
                    <h2>
                        <span class="textAlignLeft">Efficacy</span>
                    </h2>
                </div>
                <!--//eff-->
                <!--text-->
                <div class="text wow fadeIn">
                    <p>
                        In the Phase I and Phase II trials, both low-dose and high-dose patients appeared to have
                        significant changes in their ulcers – some healed completely, others decreased in size.
                    </p>
                </div>
                <!--//text-->
                <!--divider-->
                <div class="divider"></div>
                <!--//divider-->
                <!--text-->
                <div class="text wow fadeIn" id="third">
                    <!--head-->
                    <div class="head">
                        <h1>
                            <span class="pointColorText">3.</span> Engensis in ALS
                        </h1>
                    </div>
                    <!--//head-->
                    <p>
                        Amyotrophic Lateral Sclerosis (ALS), more commonly known as Lou Gehrig’s disease, is a
                        progressive
                        and fatal neuromuscular disease. ALS is characterized by the destruction of motor neurons
                        necessary
                        for the mobility muscles. There is no known cause nor identified cure for ALS.
                    </p>
                    <p>
                        16,583 patients are identified as having definite ALS in the US and the estimated prevalence of
                        the
                        disease is 5.2 per 100,000. (National ALS Registry, United States, 2015)
                    </p>
                    <p>
                        Engensis is under development to target ALS. When Engensis is injected along the peripheral
                        nerves
                        and their branches, the localized production of HGF may protect nerves and promote the growth of
                        neurons while also ameliorating atrophic conditions.
                    </p>
                    <p>
                        The US FDA granted <b>orphan drug</b> and <b>fast track designations</b> for Engensis for the
                        potential treatment
                        of ALS. With IND approved from the FDA, Phase II clinical trial of Engensis-ALS is in
                        preparation.
                    </p>
                </div>
                <!--//text-->
                <!--safety-->
                <div class="vm202Table wow fadeIn textAlignLeft">
                    <h2>
                        <span class="textAlignLeft">Safety</span>
                    </h2>
                </div>
                <!--//safety-->
                <!--text-->
                <div class="text wow fadeIn">
                    <p>
                        There have been no serious adverse events directly attributed to Engensis in the Phase I/II
                        trial,
                        except for grade 1 injection site reactions, which are resolved uneventfully. Also, the encoded
                        gene
                        is indigenous, eliminating immune response concerns possibly attached with other gene therapies.
                    </p>
                </div>
                <!--//text-->
                <!--eff-->
                <div class="vm202Table wow fadeIn textAlignLeft">
                    <h2>
                        <span class="textAlignLeft">Efficacy</span>
                    </h2>
                </div>
                <!--//eff-->
                <!--text-->
                <div class="text wow fadeIn">
                    <p>
                        ALSFRS-R (evaluating overall ALS conditions) and MRC Scale (evaluating muscle strength) from the
                        Phase I/II trial showed a trend that the ALS conditions were stabilized for 3 months after the
                        1st
                        injection of Engensis.
                    </p>
                </div>
                <!--//text-->
                <!--divider-->
                <div class="divider"></div>
                <!--//divider-->
                <!--text-->
                <div class="text wow fadeIn" id="fourth">
                    <!--head-->
                    <div class="head">
                        <h1>
                            <span class="pointColorText">4.</span> Engensis in CAD
                        </h1>
                    </div>
                    <!--//head-->
                    <p>
                        Coronary artery disease (CAD), also known as ischemic heart disease (IHD), occurs when one or
                        more of
                        the coronary arteries are narrowed or occluded, resulting in the decrease of blood supply to the
                        heart muscle.
                    </p>
                    <p>
                        IHD is the third leading cause of death worldwide. The disease recurs in 30% of the patients
                        who have received surgical procedures and medication, which are the most common treatments.
                        Furthermore, about 10% of the patient population does not respond to medication and cannot
                        undergo surgery.
                    </p>
                    <p>
                        Engensis promotes blood vessel formation in the ischemic area by HGF-based angiogenesis.
                        HGF-based angiogenesis may also contribute to cardiac muscle function improvement through the
                        suppression of apoptosis and cardiac fibrosis following myocardial infarction, a form of CAD.
                    </p>
                    <p>
                        Helixmith has completed a Phase I trial of Engensis in patients with ischemic heart disease.
                        The company is preparing to run a Phase II clinical trial in Korea using Engensis in patients
                        who had percutaneous coronary intervention (PCI) for an anterior wall infarction of the left
                        ventricle following acute myocardial infarction.
                    </p>
                </div>
                <!--//text-->
                <!--safety-->
                <div class="vm202Table wow fadeIn textAlignLeft">
                    <h2>
                        <span class="textAlignLeft">Safety</span>
                    </h2>
                </div>
                <!--//safety-->
                <!--text-->
                <div class="text wow fadeIn">
                    <p>
                        No unexpected serious adverse events or deaths were observed in the Phase I trial. HGF protein
                        levels in plasma remained stable throughout the study without any noticeable change, and
                        antibodies to human HGF proteins expressed by injection with Engensis were not detected in serum
                        during the follow-up period.
                    </p>
                </div>
                <!--//text-->
                <!--eff-->
                <div class="vm202Table wow fadeIn textAlignLeft">
                    <h2>
                        <span class="textAlignLeft">Efficacy</span>
                    </h2>
                </div>
                <!--//eff-->
                <!--text-->
                <div class="text wow fadeIn">
                    <p>
                        Engensis appeared to improve myocardial perfusion, wall thickness, and wall motion in
                        patients with angina pectoris in the Phase I trial.
                    </p>
                </div>
                <!--//text-->
            </div>
        </div>
        <!--//1-->
        <!--divider-->
        <div class="divider"></div>
        <!--//divider-->
        <!--footer-->
        <div class="footer">
            <div class="menus">
                <!-- <a href="#">
                        Privacy Policy
                    </a>
                    /
                    <a href="careers.html">
                        Careers
                    </a> -->
            </div>
            <div class="info">
                <div class="left">
                    5th Fl. Bldg. 203 Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 00826, Republic of
                    Korea<br>
                    10390 Pacific Center Ct., San Diego, CA, 92121, US<br>
                    Tel. 82.2.2102.7200 / Fax. 82.2.873.8022 / Email. contact@helixmith.com
                </div>
                <div class="right">
                    <img src="img/logo_footer.svg" /><br>
                    Copyright © 2019 Helixmith Co., Ltd. All Rights Reserved.
                </div>
            </div>
        </div>
        <!--//footer-->
    </div>
    <!--//wrapper-->
    <!--mobile Menu-->
    <div id="mobileMenu">
        <ul>
            <li>
                <a href="about_1.html">
                    Our Company
                </a>
            </li>
            <li>
                <a href="about_2.html">
                    Team Member
                </a>
            </li>
            <li>
                <a href="about_3.html">
                    Locations
                </a>
            </li>
            <li>
                <a href="vm202.html">
                    Engensis Overview
                </a>
            </li>
            <li>
                <a href="vm202_dpn.html">
                    Engensis
                </a>
            </li>
            <li>
                <a href="platform.html">
                    Platform & Technology
                </a>
            </li>
            <li>
                <a href="botanicals.html">
                    CERESMITH
                </a>
            </li>
            <li>
                <a href="#">
                    News
                </a>
            </li>
            <li>
                <a href="careers.html">
                    Careers
                </a>
            </li>
            <li>
                <div class="button" id="hidePanel">
                    <img src="img/close_ico.svg" />
                </div>
            </li>
        </ul>
    </div>
    <!--//mobile Menu-->
    <!--js-->
    <script src="js/wow.js"></script>
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.11.1/jquery.min.js"></script>

    <script>
        wow = new WOW(
            {
                animateClass: 'animated',
                offset: 100,
                callback: function (box) {
                    console.log("WOW: animating <" + box.tagName.toLowerCase() + ">")
                }
            }
        );
        wow.init();

        $(document).ready(function () {

            $("#showPanel").click(function () {
                $("#mobileMenu").show();
            });

            $("#hidePanel").click(function () {
                $("#mobileMenu").hide();
            });

        });
    </script>
    <!--//js-->
</body>

</html>